Alterity Therapeutics Limited
ATHE
$4.60
-$0.10-2.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 75.89% | 72.58% | -15.53% | -13.55% | 36.54% |
| Total Revenue | 75.89% | 72.58% | -15.53% | -13.55% | 36.54% |
| Cost of Revenue | -47.03% | -47.93% | -34.49% | -32.81% | -7.42% |
| Gross Profit | 83.08% | 79.67% | -14.51% | -12.51% | 40.48% |
| SG&A Expenses | -21.89% | -23.35% | 60.58% | 64.34% | 20.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,860.00% | 1,820.00% | 1,433.33% | 1,475.00% | -61.54% |
| Total Operating Expenses | -29.51% | -30.83% | 7.33% | 9.84% | 91.58% |
| Operating Income | 46.70% | 47.70% | -13.88% | -16.55% | -105.06% |
| Income Before Tax | 62.06% | 62.77% | -10.22% | -12.80% | -114.77% |
| Income Tax Expenses | 43.42% | 40.13% | -- | -- | 7,500.00% |
| Earnings from Continuing Operations | 61.67% | 62.39% | -10.22% | -12.80% | -115.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.67% | 62.39% | -10.22% | -12.80% | -115.53% |
| EBIT | 46.70% | 47.70% | -13.88% | -16.55% | -105.06% |
| EBITDA | 46.72% | 47.72% | -13.95% | -16.61% | -105.39% |
| EPS Basic | 77.78% | 77.78% | 50.00% | 44.44% | -12.50% |
| Normalized Basic EPS | 60.00% | 60.00% | 40.00% | 40.00% | 0.00% |
| EPS Diluted | 77.78% | 77.78% | 37.50% | 44.44% | -12.50% |
| Normalized Diluted EPS | 60.00% | 60.00% | 40.00% | 40.00% | 0.00% |
| Average Basic Shares Outstanding | 56.02% | 56.02% | 112.26% | 112.26% | 96.21% |
| Average Diluted Shares Outstanding | 56.02% | 56.02% | 112.26% | 112.26% | 96.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |